Market Cap 8.85B
Revenue (ttm) 0.00
Net Income (ttm) -766.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,683,400
Avg Vol 1,028,116
Day's Range N/A - N/A
Shares Out 148.81M
Stochastic %K 27%
Beta 1.22
Analysts Strong Sell
Price Target $109.00

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 0111
Website: vaxcyte.com
Address:
825 Industrial Road, Suite 300, San Carlos, United States
JeremyDanie
JeremyDanie Sep. 8 at 6:43 PM
$PCVX buying
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:59 PM
$PCVX End of October is the big date.
0 · Reply
topstockalerts
topstockalerts Sep. 4 at 2:27 AM
Vaxcyte announced the appointment of two senior executives and provided a more specific timeline for data from its VAX-31 pneumococcal vaccine program. The clinical-stage vaccine company named Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. It also expects preliminary safety, tolerability and immunogenicity data from the Phase 3 OPUS-1 trial in adults by the end of October 2026, narrowing its previous guidance to the fourth quarter. Jodar joins from Pfizer, where he spent 17 years and most recently served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases, overseeing programs including Prevnar 13, Prevnar 20, Abrysvo, Comirnaty and Paxlovid. McAvoy brings more than 30 years of biopharmaceutical legal experience, most recently as Teva’s Executive Vice President and Chief Legal Officer, after senior roles at Endocyte and Eli Lilly. $PCVX
0 · Reply
TeresaTrades
TeresaTrades Sep. 2 at 1:58 PM
Largest PUT OI Increases $NVDA $PFE $GPRO $PCVX $NCLH
0 · Reply
G101SPM
G101SPM Sep. 1 at 6:32 PM
#OPTIONACTION $GME Dec '28 32.0 calls (volume: 1.1K, open int: 160, implied vol: ~49%, prev day implied vol: 46%). Co is expected to report earnings mid-September. $NN Dec 21.0 calls (volume: 22.7K, open int: 140, implied vol: ~114%, prev day implied vol: 84%). $GPRO Sep 1.5 calls (volume: 55.8K, open int: 1.7K, implied vol: ~141%, prev day implied vol: 132%). Underlying stock is trading higher by 42%. GoPro entered into a definitive merger agreement - shareholders will receive an aggregate cash payment of $285 mln, or $1.14 per share, subject to potential adjustment. $PCVX Dec 30.0 puts (volume: 21.9K, open int: 680, implied vol: ~50%, prev day implied vol: 46%). Co is expected to report earnings mid-November. $PSKY Jan '27 6.0 puts (volume: 10.5K, open int: 10.5K, implied vol: ~48%, prev day implied vol: 42%). Underlying stock is trading lower by 4%. Co is expected to report earnings mid-November.
1 · Reply
kiwitc2000
kiwitc2000 Sep. 1 at 4:06 PM
$PCVX Still testing historic resistance around 62. On watch.
0 · Reply
Doozio
Doozio Aug. 19 at 11:28 PM
$PCVX it was always ENTA 🐒🍌🧠⏰♾️
0 · Reply
OptionRunners
OptionRunners Aug. 19 at 5:57 PM
$PCVX October call buyer for $842K
0 · Reply
TheKogaa
TheKogaa Aug. 19 at 4:25 PM
0 · Reply
GangsterX
GangsterX Aug. 19 at 12:04 PM
$PCVX They will pass phase 3 in Q4. This is another vaccine. This stock will pass 100 after vaccine data in Q4. Keep an eye on this one... Really? Hellll Yahhh!
0 · Reply
Latest News on PCVX
Vaxcyte narrows previously communicated VAX-31 guidance

2026-09-03T20:30:18.000Z - 9 days ago

Vaxcyte narrows previously communicated VAX-31 guidance


Vaxcyte Slides: Corporate presentation

Sep 3, 2026, 7:00 AM EDT - 9 days ago

Vaxcyte Slides: Corporate presentation


Vaxcyte to Participate in Upcoming Investor Conferences

Aug 27, 2026, 4:05 PM EDT - 16 days ago

Vaxcyte to Participate in Upcoming Investor Conferences


Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)

2026-08-05T20:50:42.000Z - 5 weeks ago

Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)


Vaxcyte Slides: Corporate presentation

Aug 5, 2026, 8:00 AM EDT - 5 weeks ago

Vaxcyte Slides: Corporate presentation


Vaxcyte Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Vaxcyte Quarterly report: Q2 2026


Vaxcyte Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Vaxcyte Earnings release: Q2 2026


Vaxcyte Transcript: AGM 2026

Jun 15, 2026, 11:30 AM EDT - 2 months ago

Vaxcyte Transcript: AGM 2026


Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 3 months ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026


Vaxcyte doses first participant in VAX-A1 study

2026-06-02T20:28:55.000Z - 3 months ago

Vaxcyte doses first participant in VAX-A1 study


Vaxcyte Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 3 months ago

Vaxcyte Slides: Corporate presentation


Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)

2026-05-07T01:27:16.000Z - 4 months ago

Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)


Vaxcyte Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 4 months ago

Vaxcyte Quarterly report: Q1 2026


Vaxcyte Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 4 months ago

Vaxcyte Earnings release: Q1 2026


Vaxcyte Slides: Corporate presentation

May 5, 2026, 6:00 PM EDT - 4 months ago

Vaxcyte Slides: Corporate presentation


Vaxcyte Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vaxcyte Proxy statement: Proxy filing


Vaxcyte Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vaxcyte Proxy statement: Proxy filing


Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial

2026-03-23T13:06:31.000Z - 5 months ago

Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial


Vaxcyte Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Vaxcyte Slides: Corporate presentation


Vaxcyte Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:00 PM EDT - 6 months ago

Vaxcyte Transcript: Leerink Global Healthcare Conference 2026


Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 6 months ago

Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference


Vaxcyte price target raised to $89 from $85 at BTIG

2026-02-26T01:15:13.000Z - 6 months ago

Vaxcyte price target raised to $89 from $85 at BTIG


Vaxcyte price target lowered to $133 from $134 at BofA

2026-02-25T15:10:32.000Z - 6 months ago

Vaxcyte price target lowered to $133 from $134 at BofA


Vaxcyte price target raised to $67 from $38 at Goldman Sachs

2026-02-25T13:06:55.000Z - 6 months ago

Vaxcyte price target raised to $67 from $38 at Goldman Sachs


Vaxcyte price target raised to $75 from $50 at TD Cowen

2026-02-25T12:50:02.000Z - 6 months ago

Vaxcyte price target raised to $75 from $50 at TD Cowen


Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year

2026-02-24T21:38:10.000Z - 6 months ago

Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year


Vaxcyte Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Vaxcyte Earnings Call Transcript: Q4 2025


Vaxcyte Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Vaxcyte Annual report: Q4 2025


Vaxcyte Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Vaxcyte Earnings release: Q4 2025


Vaxcyte Slides: Corporate presentation

Feb 24, 2026, 4:00 PM EST - 6 months ago

Vaxcyte Slides: Corporate presentation


Vaxcyte doses first participants in OPUS-3 trial

2026-02-11T21:30:50.000Z - 7 months ago

Vaxcyte doses first participants in OPUS-3 trial


Vaxcyte Slides: Corporate presentation

Feb 11, 2026, 7:00 AM EST - 7 months ago

Vaxcyte Slides: Corporate presentation


Vaxcyte 11M share Spot Secondary priced at $50.00

2026-01-30T11:06:07.000Z - 7 months ago

Vaxcyte 11M share Spot Secondary priced at $50.00


Vaxcyte Announces Pricing of $550 Million Public Offering

Jan 29, 2026, 11:33 PM EST - 7 months ago

Vaxcyte Announces Pricing of $550 Million Public Offering


Vaxcyte secondary being re-offered at $50 per share

2026-01-30T00:45:09.000Z - 7 months ago

Vaxcyte secondary being re-offered at $50 per share


Vaxcyte offering marketed at $50 per share, Bloomberg says

2026-01-29T22:55:17.000Z - 7 months ago

Vaxcyte offering marketed at $50 per share, Bloomberg says


Needham ups Vaxcyte target, adds to Conviction List

2026-01-07T11:20:26.000Z - 8 months ago

Needham ups Vaxcyte target, adds to Conviction List

PHAT


Vaxcyte Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 9 months ago

Vaxcyte Transcript: Jefferies London Healthcare Conference 2025


Vaxcyte Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 10 months ago

Vaxcyte Slides: Corporate Presentation


Vaxcyte Earnings release: Q3 2025

Nov 4, 2025, 7:00 AM EST - 10 months ago

Vaxcyte Earnings release: Q3 2025


Vaxcyte Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 10 months ago

Vaxcyte Quarterly report: Q3 2025


Vaxcyte Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 1 year ago

Vaxcyte Transcript: Cantor Global Healthcare Conference 2025


Vaxcyte Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Quarterly report: Q2 2025


Vaxcyte Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Earnings release: Q2 2025


Vaxcyte Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 11:40 AM EDT - 1 year ago

Vaxcyte Transcript: BofA Securities 2025 Healthcare Conference


Vaxcyte Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Earnings release: Q1 2025


Vaxcyte Quarterly report: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Quarterly report: Q1 2025


Vaxcyte Slides: Investor Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Vaxcyte Slides: Investor Presentation


Vaxcyte Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing


Vaxcyte Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing


Vaxcyte Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing


Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 1 year ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI


Vaxcyte Transcript: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Transcript: Study Result


Vaxcyte Press release: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Press release: Study Result


Vaxcyte Slides: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Slides: Study Result


Vaxcyte Earnings Call Transcript: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Earnings Call Transcript: Q4 2024


Vaxcyte Annual report: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Annual report: Q4 2024


Vaxcyte Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Earnings release: Q4 2024


Vaxcyte Slides: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Slides: Q4 2024


Vaxcyte Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

Vaxcyte Transcript: Guggenheim SMID Cap Biotech Conference


Vaxcyte Quarterly report: Q3 2024

Nov 5, 2024, 4:00 PM EST - 1 year ago

Vaxcyte Quarterly report: Q3 2024


Vaxcyte Earnings release: Q3 2024

Nov 5, 2024, 4:00 PM EST - 1 year ago

Vaxcyte Earnings release: Q3 2024


Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 4, 2024, 11:58 PM EDT - 2 years ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering


Vaxcyte Transcript: Study Result

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Transcript: Study Result


Vaxcyte Slides: Study Result

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Slides: Study Result


Vaxcyte Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Quarterly report: Q2 2024


Vaxcyte Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Earnings release: Q2 2024


Vaxcyte Appoints John Furey to Board of Directors

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Vaxcyte Appoints John Furey to Board of Directors


Vaxcyte Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference


Vaxcyte Transcript: Bank of America Health Care Conference 2024

May 14, 2024, 12:20 PM EDT - 2 years ago

Vaxcyte Transcript: Bank of America Health Care Conference 2024


Vaxcyte Slides: Investor Presentation

May 10, 2024, 2:00 PM EDT - 2 years ago

Vaxcyte Slides: Investor Presentation


Vaxcyte Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Quarterly report: Q1 2024


Vaxcyte Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Earnings release: Q1 2024


Vaxcyte Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Proxy statement: Proxy Filing


Vaxcyte Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Proxy statement: Proxy Filing


JeremyDanie
JeremyDanie Sep. 8 at 6:43 PM
$PCVX buying
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:59 PM
$PCVX End of October is the big date.
0 · Reply
topstockalerts
topstockalerts Sep. 4 at 2:27 AM
Vaxcyte announced the appointment of two senior executives and provided a more specific timeline for data from its VAX-31 pneumococcal vaccine program. The clinical-stage vaccine company named Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. It also expects preliminary safety, tolerability and immunogenicity data from the Phase 3 OPUS-1 trial in adults by the end of October 2026, narrowing its previous guidance to the fourth quarter. Jodar joins from Pfizer, where he spent 17 years and most recently served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases, overseeing programs including Prevnar 13, Prevnar 20, Abrysvo, Comirnaty and Paxlovid. McAvoy brings more than 30 years of biopharmaceutical legal experience, most recently as Teva’s Executive Vice President and Chief Legal Officer, after senior roles at Endocyte and Eli Lilly. $PCVX
0 · Reply
TeresaTrades
TeresaTrades Sep. 2 at 1:58 PM
Largest PUT OI Increases $NVDA $PFE $GPRO $PCVX $NCLH
0 · Reply
G101SPM
G101SPM Sep. 1 at 6:32 PM
#OPTIONACTION $GME Dec '28 32.0 calls (volume: 1.1K, open int: 160, implied vol: ~49%, prev day implied vol: 46%). Co is expected to report earnings mid-September. $NN Dec 21.0 calls (volume: 22.7K, open int: 140, implied vol: ~114%, prev day implied vol: 84%). $GPRO Sep 1.5 calls (volume: 55.8K, open int: 1.7K, implied vol: ~141%, prev day implied vol: 132%). Underlying stock is trading higher by 42%. GoPro entered into a definitive merger agreement - shareholders will receive an aggregate cash payment of $285 mln, or $1.14 per share, subject to potential adjustment. $PCVX Dec 30.0 puts (volume: 21.9K, open int: 680, implied vol: ~50%, prev day implied vol: 46%). Co is expected to report earnings mid-November. $PSKY Jan '27 6.0 puts (volume: 10.5K, open int: 10.5K, implied vol: ~48%, prev day implied vol: 42%). Underlying stock is trading lower by 4%. Co is expected to report earnings mid-November.
1 · Reply
kiwitc2000
kiwitc2000 Sep. 1 at 4:06 PM
$PCVX Still testing historic resistance around 62. On watch.
0 · Reply
Doozio
Doozio Aug. 19 at 11:28 PM
$PCVX it was always ENTA 🐒🍌🧠⏰♾️
0 · Reply
OptionRunners
OptionRunners Aug. 19 at 5:57 PM
$PCVX October call buyer for $842K
0 · Reply
TheKogaa
TheKogaa Aug. 19 at 4:25 PM
0 · Reply
GangsterX
GangsterX Aug. 19 at 12:04 PM
$PCVX They will pass phase 3 in Q4. This is another vaccine. This stock will pass 100 after vaccine data in Q4. Keep an eye on this one... Really? Hellll Yahhh!
0 · Reply
TheKogaa
TheKogaa Aug. 17 at 6:42 PM
$PCVX added this morning bc I have a strong feeling Here is the data: Here is a summary of pdf PCVX INVESTMENT SUMMARY — 1 BINARY EVENT SETUP PCVX is a pre-revenue clinical-stage vaccine ($58.07) betting entirely on VAX-31’s Phase 3 OPUS-1 readout in Q4 2026. Success = rerates to $100-110+; failure = 50%+ drawdown. It’s a binary all-or-nothing bet. 2 SUPERIOR COVERAGE MATTERS CLINICALLY VAX-31 covers 31 serotypes (~95% disease coverage) vs. Pfizer Prevnar 20 (20 types, ~52%) and Merck Capvaxive (21 types, ~84%). The extra 10 serotypes VAX-31 covers cause high-fatality, antibiotic-resistant infections that competitors leave unprotected—that’s the commercial thesis. 3 TIMING: NOVEMBER 5, 2026 IS MOST LIKELY Based on competitor precedent (Pfizer, Merck announcements), PCVX will likely announce OPUS-1 topline data on Tuesday, November 5, 2026, pre-market (~7:30am ET). This is your catalyst date for options strategy.
1 · Reply
TheKogaa
TheKogaa Aug. 17 at 2:27 PM
$PCVX ome November I predicted this is gonna be $100 Mark it
0 · Reply
infiniteM
infiniteM Aug. 12 at 4:20 PM
$PCVX still incredibly overvalued. even if the drug works... they can't scale.
0 · Reply
G101SPM
G101SPM Jul. 24 at 2:12 PM
#SHOWTIME International AIDS Conference (July 27-31) Scheduled to appear: $MRK BTIG Biotechnology Conference (July 27) Scheduled to appear: $DNLI, $MLTX, $PCVX
0 · Reply
Maldof
Maldof Jul. 17 at 11:10 AM
$ATAI After taking my profits from here, this are my next stocks: $NVO $EYPT $PCVX $NWPHF
1 · Reply
JPB415
JPB415 Jul. 7 at 7:47 PM
$PCVX Can’t believe I sold this for $RKLB FUCK!
0 · Reply
BB_king
BB_king Jul. 7 at 5:56 PM
$PCVX should I have bought at a cheaper price? Yes Did I still buy today? Also yes
0 · Reply
QuantInsider
QuantInsider Jun. 29 at 9:33 PM
$PCVX popped 11% this week with the Russell 2000 Growth index addition But options traders just dropped over $11M on long-dated, 22% OTM puts today Looks like someone’s loading up on downside protection while the stock’s riding high Today's entire options premium went into Dec 18, 2026 $45 puts That's a big bet on six-month downside, making fresh unhedged longs look riskier With PCVX up 11.26% over 5 days, today's 2.12% gain seems more about index demand than new fundamentals Momentum players should watch out for a post inclusion fade, especially with this surge in protective puts
0 · Reply
infiniteM
infiniteM Jun. 29 at 7:19 PM
$PCVX wow someone check out puts for 12/18 that's some unusual flow
0 · Reply
Edgebell
Edgebell Jun. 25 at 1:05 PM
$IWM Small caps move faster, further, and require tight execution. If you aren't scanning the Russell 2000 for high-probability setups, you're missing out on major alpha. 📈 The EdgeBell IWM Scanner runs a comprehensive, proprietary multi-point technical checklist to surface top-tier small-cap setups instantly. Whether it's finding an oversold stochastic cross on $AXTI or a massive volume breakout on $PCVX, EdgeBell grades them all on a clear scale (like +6/-6) so you know exactly where the edge is. 🔥 NEW FEATURE: We don't just scan the charts—we scan the tape. EdgeBell now includes our automated Options Sweep Alerts Scoring System. We track institutional unusual options flow, score the sweeps, and alert you to where the smartest money is aggressively positioning. Stop guessing which small caps are ready to run. Let EdgeBell do the heavy lifting. 👉 http://EdgeBell.io/options
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 21 at 3:29 PM
$PCVX Vaxcyte (PCVX) is drawing attention with a 123.85% upside estimate, a $7.09 billion market cap, and a first-in-human vaccine trial targeting Group A Strep, a disease with no approved vaccine. https://biotechhealthx.com/biotech-news/could-vaxcyte-inc-pcvx-be-one-of-the-most-promising-vaccine-stocks-in-biotech/
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 21 at 10:06 AM
$COGT $INSM $LEGN $PCVX $SMMT These 5 healthcare stocks are drawing attention from Wall Street analysts because of strong stock upside, clinical trial updates, market expansion, biotech innovation, and major healthcare growth catalysts. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-that-could-turn-a-1000-investment-into-something-bigger/
0 · Reply